stockrow
Friday 6 November 2026
Export CDNA’s income statement to Excel — free account
CareDx, Inc.
CDNA Healthcare Diagnostics & Research
CareDx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $379.8 million, up 13.8% from fiscal 2024.
- Revenue
- +39.3%
- EPS
- +1,134.0%
- Free cash flow
- −68.6%
Quarter to September 2026, against a year earlier
78.10
1.77
+2.32%
Follow CDNA
Alert me
CareDx, Inc. (CDNA) P/E ratio
As of 6 November 2026, CareDx, Inc. (CDNA) trades at a P/E ratio of 31.4×. Over the past ten years it has ranged from 0.0× (June 2026) to 35.5× (November 2026); the current reading is higher than 100% of that period. That is below the Diagnostics & Research industry median of 35.2× and above the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 22.5× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 26.1× | 96.91% |
| Jun 2026 | 13.3× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 43 more quarters | Free account |
Against its own ten years
Low 0.0×
High 35.5×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| WGS GeneDx Holdings Corp. compare | n/m |
| RDNT RadNet, Inc. compare | n/m |
| NEO NeoGenomics, Inc. compare | n/m |
| GRAL GRAIL, Inc. compare | n/m |
| ADPT Adaptive Biotechnologies Corporation compare | n/m |
| VCYT Veracyte, Inc. compare | 15.2× |
| SHC Sotera Health Company compare | 26.4× |
| CDNA CareDx, Inc. | 31.4× |
| BLLN BillionToOne, Inc. compare | 89.9× |
| Diagnostics & Research industry median | 35.2× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on CDNA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement